Skip to content
Screener

Income Tax at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$15.8M+148%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$11.37M+1,669%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%
Mannkind logo
MannkindMNKD
-$106K-139%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$20K-73.0%
Opko Health logo
Opko HealthOPK
-$4.98M+64.6%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Income from operations27,19420,16056,46133,432
Other income, net3,9512,7177,3655,010
Income before income taxes31,14522,87763,82638,442
Provision for income taxes(5,713)(5,045)(15,802)(12,071)
Net income$25,432$17,832$48,024$26,371
Net income per share attributable to ordinary shareholders—basic$0.33$0.24$0.62$0.36
Net income per share attributable to ordinary shareholders—diluted$0.30$0.23$0.58$0.34
Weighted average ordinary shares outstanding—basic77,577,67573,438,53077,050,03673,041,920

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's income tax?
Kiniksa Pharmaceuticals International, plc (KNSA) reported income tax of $5.71M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's income tax changed year-over-year?
Kiniksa Pharmaceuticals International, plc's income tax increased by 13.2% year-over-year, from $5.05M to $5.71M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's income tax?
Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's income tax has grown at a 178.3% compound annual growth rate (CAGR), from $1.39M to $29.86M.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Kiniksa Pharmaceuticals International, plc's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude